摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2,6-二氟-4-溴苯基)吗啉 | 1408074-69-0

中文名称
4-(2,6-二氟-4-溴苯基)吗啉
中文别名
——
英文名称
4-(4-bromo-2,6-difluoro-phenyl)morpholine
英文别名
4-(4-Bromo-2,6-difluorophenyl)morpholine
4-(2,6-二氟-4-溴苯基)吗啉化学式
CAS
1408074-69-0
化学式
C10H10BrF2NO
mdl
——
分子量
278.096
InChiKey
SCOXKNUXXYBFHW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    4-(2,6-二氟-4-溴苯基)吗啉 、 methyl 3-amino-5-(methylamino)-6-(3-methylimidazo[4,5-c]pyridin-7-yl)pyrazine-2-carboxylate 在 [(2-di-cyclohexylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1‘-biphenyl)-2-(2‘-amino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 caesium carbonate 作用下, 以 1,4-二氧六环 为溶剂, 以46 %的产率得到methyl 3-(3,5-difluoro-4-morpholino-anilino)-5-(methylamino)-6-(3-methylimidazo[4,5-c]pyridin-7-yl)pyrazine-2-carboxylate
    参考文献:
    名称:
    [EN] SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
    [FR] PYRAZINE-2-CARBOXAMIDES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HPK1 POUR LE TRAITEMENT DU CANCER
    摘要:
    There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoietic progenitor kinase 1 (HPK1) and are thereby particularly useful in the treatment or prophylaxis of cancer.
    公开号:
    WO2023001794A1
点击查看最新优质反应信息

文献信息

  • [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER AVEC CEUX-CI
    申请人:UNIV HEALTH NETWORK
    公开号:WO2010115279A1
    公开(公告)日:2010-10-14
    The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    这项发明涉及一种由以下结构式表示的化合物及其药用可接受的盐:由该结构式表示的化合物是激酶抑制剂,因此在此披露用于治疗癌症。结构式中变量的定义在此提供。
  • KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    申请人:University Health Network
    公开号:EP2417127A1
    公开(公告)日:2012-02-15
  • [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER UTILISANT CEUX-CI
    申请人:UNIV HEALTH NETWORK
    公开号:WO2011123946A1
    公开(公告)日:2011-10-13
    The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
查看更多